
## Michael D Decker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7664105/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pertussis (Whooping Cough). Journal of Infectious Diseases, 2021, 224, S310-S320.	1.9	25
2	Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members. Vaccine, 2021, 39, 5541-5547.	1.7	18
3	Brand-specific rates of pertussis disease among Wisconsin children given 1–4 doses of pertussis Vaccine, 2010–2014. Vaccine, 2020, 38, 7063-7069.	1.7	3
4	Prospective safety surveillance study of ACAM2000 smallpox vaccine in deploying military personnel. Vaccine, 2020, 38, 7323-7330.	1.7	18
5	One Confirmed and 2 Suspected Cases of Heartland Virus Disease. Clinical Infectious Diseases, 2020, 71, 3237-3240.	2.9	3
6	Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP. Vaccine, 2019, 37, 5003-5008.	1.7	5
7	Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 105-114.	0.6	17
8	Humoral immunity 10†years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA. Vaccine, 2018, 36, 2282-2287.	1.7	29
9	Pertussis Vaccines. , 2018, , 711-761.e16.		20
10	Combination Vaccines. , 2018, , 198-227.e13.		10
11	Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth. Journal of the Pediatric Infectious Diseases Society, 2017, 6, e69-e74.	0.6	10
12	Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65Ây of age and older. Human Vaccines and Immunotherapeutics, 2017, 13, 2058-2064.	1.4	8
13	Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers. Vaccine, 2016, 34, 4172-4179.	1.7	23
14	Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Vaccine, 2016, 34, 5273-5278.	1.7	16
15	Fluzone® High-Dose Influenza Vaccine. Expert Review of Vaccines, 2016, 15, 1495-1505.	2.0	45
16	Highly differentiated human airway epithelial cells: a model to study host cell–parasite interactions in pertussis. Infectious Diseases, 2016, 48, 177-188.	1.4	20
17	Estimating the Effectiveness of Tetanus-Diphtheria-Acellular Pertussis Vaccine. Journal of Infectious Diseases, 2015, 211, 497-498.	1.9	5
18	Regarding Primary Care Patients Who Received Influenza Vaccine at Veteran Health Administration Medical Centers. Clinical Infectious Diseases, 2015, 61, 1344-1345.	2.9	5

#	Article	IF	CITATIONS
19	Safety and Immunogenicity of an Inactivated Quadrivalent Influenza Vaccine in Children 6 Months through 8 Years of Age. Pediatric Infectious Disease Journal, 2014, 33, 630-636.	1.1	42
20	Safety and Immunogenicity of Tetanus-Diphtheria-Acellular Pertussis Vaccine Administered to Children 10 or 11 Years of Age. Vaccine Journal, 2014, 21, 1560-1564.	3.2	4
21	Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults. New England Journal of Medicine, 2014, 371, 635-645.	13.9	636
22	Combination vaccines. , 2013, , 981-1007.		7
23	Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine, 2013, 31, 770-776.	1.7	102
24	Pertussis vaccines. , 2013, , 447-492.		32
25	Immune Responses in Infants Whose Mothers Received Tdap Vaccine During Pregnancy. Pediatric Infectious Disease Journal, 2013, 32, 1257-1260.	1.1	131
26	Methodological Issues With the Risk of Relapse Study in Patients With Multiple Sclerosis After Yellow Fever Vaccination. Archives of Neurology, 2012, 69, 144.	4.9	12
27	Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in 2- to 10-year-old Human Immunodeficiency Virus-infected Children. Pediatric Infectious Disease Journal, 2012, 31, 47-52.	1.1	32
28	Immunogenicity and Safety of 1 vs 2 Doses of Quadrivalent Meningococcal Conjugate Vaccine in Youth Infected with Human Immunodeficiency Virus. Journal of Pediatrics, 2012, 161, 676-681.e2.	0.9	38
29	Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine, 2012, 30, 974-982.	1.7	47
30	Phase I/II, Open-Label Trial of Safety and Immunogenicity of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Human Immunodeficiency Virus-Infected Adolescents. Pediatric Infectious Disease Journal, 2010, 29, 391-396.	1.1	51
31	Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine in Infants. Pediatric Infectious Disease Journal, 2010, 29, 105-110.	1.1	44
32	Reactogenicity of Tetanus, Diphtheria, 5-Component Acellular Pertussis Vaccine Administered as a Sixth Consecutive Acellular Pertussis Vaccine Dose to Adolescents. Pediatric Infectious Disease Journal, 2010, 29, 1067-1071.	1.1	10
33	Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever. Vaccine, 2010, 28, 1451-1453.	1.7	21
34	Kinetics of Pertussis Immune Responses to Tetanusâ€Điphtheriaâ€Acellular Pertussis Vaccine in Health Care Personnel: Implications for Outbreak Control. Clinical Infectious Diseases, 2009, 49, 584-587.	2.9	25
35	THE USE AND EFFICACY OF CHILD RESTRAINT DEVICES. American Journal of Public Health, 2009, 99, 1160-1160.	1.5	2
36	Trivalent Inactivated Influenza Virus Vaccine Given to Two-Month-Old Children. Pediatric Infectious Disease Journal, 2009, 28, 1099-1104.	1.1	36

#	Article	IF	CITATIONS
37	Prospective Assessment of the Effect of Needle Length and Injection Site on the Risk of Local Reactions to the Fifth Diphtheria-Tetanus-Acellular Pertussis Vaccination. Pediatrics, 2008, 121, e646-e652.	1.0	25
38	Respiratory Syncytial Virus Infection in Patients with Hematological Diseases: Single-Center Study and Review of the Literature. Clinical Infectious Diseases, 2008, 46, 402-412.	2.9	219
39	Pertussis vaccines. , 2008, , 467-517.		18
40	Combination vaccines. , 2008, , 1069-1101.		6
41	Cellular Immunity in Adolescents and Adults following Acellular Pertussis Vaccine Administration. Vaccine Journal, 2007, 14, 288-292.	3.2	34
42	How Soon After a Prior Tetanus-Diphtheria Vaccination Can One Give Adult Formulation Tetanus-Diphtheria-Acellular Pertussis Vaccine?. Pediatric Infectious Disease Journal, 2006, 25, 195-200.	1.1	82
43	Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan. Biologicals, 2005, 33, 59.	0.5	0
44	Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology, 2005, 65, 1964-1966.	1.5	63
45	Role of Pertactin in Pertussis Vaccines: The Jury Is Still Out. Journal of Infectious Diseases, 2004, 189, 1332-1333.	1.9	0
46	Prevalence of Antibody toBordetella pertussisAntigens in Serum Specimens Obtained from 1793 Adolescents and Adults. Clinical Infectious Diseases, 2004, 39, 1715-1718.	2.9	30
47	Establishment of Diagnostic Cutoff Points for Levels of Serum Antibodies to Pertussis Toxin, Filamentous Hemagglutinin, and Fimbriae in Adolescents and Adults in the United States. Vaccine Journal, 2004, 11, 1045-1053.	2.6	118
48	Letter to the Editor. Vaccine, 2004, 22, 2681-2684.	1.7	6
49	Strengthening the Supply of Routinely Recommended Vaccines in the United States. JAMA - Journal of the American Medical Association, 2003, 290, 3122.	3.8	57
50	Lack of consistent relationship between quantity of aluminum in diphtheria–tetanus–acellular pertussis vaccines and rates of extensive swelling reactions. Vaccine, 2002, 20, S44-S47.	1.7	29
51	Change and Constancy, 2002. Infection Control and Hospital Epidemiology, 2002, 23, 10-10.	1.0	1
52	Combination Vaccines. Infectious Disease Clinics of North America, 2001, 15, 209-230.	1.9	17
53	Combination vaccines. Primary Care - Clinics in Office Practice, 2001, 28, 739-761.	0.7	4
54	Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatric Infectious Disease Journal, 2001, 20, S10-S18.	1.1	71

#	Article	IF	CITATIONS
55	Combination vaccines: Problems and promise. Journal of Pediatrics, 2000, 137, 291-295.	0.9	21
56	ACELLULAR PERTUSSIS VACCINES. Pediatric Clinics of North America, 2000, 47, 309-335.	0.9	37
57	A Randomized Clinical Trial of Acellular Pertussis Vaccines in Healthy Adults: Doseâ€Response Comparisons of 5 Vaccines and Implications for Booster Immunization. Journal of Infectious Diseases, 1999, 180, 397-403.	1.9	65
58	An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Vaccine, 1999, 17, 2999-3006.	1.7	23
59	Incidence of Pertussis Infection in Healthcare Workers. Infection Control and Hospital Epidemiology, 1999, 20, 120-123.	1.0	77
60	Issues for Health Practitioners in the Use of Combination Vaccines. , 1999, , 249-267.		0
61	International variation in the management of infants hospitalized with respiratory syncytial virus. European Journal of Pediatrics, 1998, 157, 215-220.	1.3	164
62	Haemophilus influenzae type b vaccines: history, choice and comparisons. Pediatric Infectious Disease Journal, 1998, 17, S113-S116.	1.1	31
63	Prevalence of Positive Serology for Acute <i>Chlamydia pneumoniae</i> Infection in Emergency Department Patients with Persistent Cough. Academic Emergency Medicine, 1997, 4, 179-183.	0.8	25
64	Combination vaccines consisting of acellular pertussis vaccines. Pediatric Infectious Disease Journal, 1997, 16, S97-S102.	1.1	34
65	Acellular Pertussis Vaccines for Infants. New England Journal of Medicine, 1996, 334, 391-392.	13.9	73
66	Challenges for Licensure of New Diphtheria, Tetanus Toxoid, Acellular Pertussis (DTaP) Combination Vaccines: Counterpoint. Pediatric Infectious Disease Journal, 1996, 15, 1070-1073.	1.1	11
67	Who should receive hepatitis A vaccine?. Pediatric Infectious Disease Journal, 1995, 14, 258-260.	1.1	17
68	Issues in Design of Clinical Trials of Combination Vaccines. Annals of the New York Academy of Sciences, 1995, 754, 234-240.	1.8	20
69	Pertussis seroprevalence in emergency department staff. Annals of Emergency Medicine, 1994, 24, 413-417.	0.3	18
70	Combination vaccines. Pediatric Infectious Disease Journal, 1994, 13, 345-347.	1.1	38
71	Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatric Infectious Disease Journal, 1994, 13, 635-639.	1.1	38
72	Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal, 1994, 13, 206-211.	1.1	74

#	Article	IF	CITATIONS
73	Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid. Journal of Pediatrics, 1993, 122, 410-413.	0.9	23
74	Psychoactive Drugs and the Risk of Injurious Motor Vehicle Crashes in Elderly Drivers. American Journal of Epidemiology, 1992, 136, 873-883.	1.6	381
75	Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. Journal of Pediatrics, 1992, 120, 184-189.	0.9	235
76	Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. Journal of Pediatrics, 1992, 121, 523-527.	0.9	61
77	Medications and the Safety of the Older Driver: Is There a Basis for Concern?. Human Factors, 1992, 34, 33-47.	2.1	47
78	Case Report: Fatal Pulmonary Toxoplasmosis Following Chemotherapy. American Journal of the Medical Sciences, 1991, 302, 152-154.	0.4	6
79	Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines. Pediatric Infectious Disease Journal, 1991, 10, 315-318.	1.1	16
80	The Development of Indicators. Infection Control and Hospital Epidemiology, 1991, 12, 490-492.	1.0	6
81	Association of self-reported injury and alcohol consumption in medical outpatients. Journal of General Internal Medicine, 1990, 5, 486-489.	1.3	9
82	Motor Vehicle Fatalities and the Minimum Drinking Age-Reply. JAMA - Journal of the American Medical Association, 1989, 261, 3411.	3.8	0
83	Reply: Recurrent Broviac Catheter Infections. Journal of Infectious Diseases, 1988, 157, 214-214.	1.9	0
84	MANAGEMENT OF CATHETER-RELATED BACTEREMIA. Pediatric Infectious Disease Journal, 1988, 7, 303.	1.1	0
85	Central Venous Catheter Infections. Pediatric Clinics of North America, 1988, 35, 579-612.	0.9	166
86	Description of Case-Mix Adjusters by the Severity of Illness Working Group of The Society of Hospital Epidemiologists of America (SHEA). Infection Control and Hospital Epidemiology, 1988, 9, 309-316.	1.0	13
87	Intravenous Therapy: Expanding the Bounds of Safety. JAMA - Journal of the American Medical Association, 1987, 258, 2418.	3.8	1
88	Eikenella corrodens. Infection Control, 1986, 7, 36-41.	0.5	18
89	Endocarditis and Infections of Intravascular Devices Due to Eikenella corrodens. American Journal of the Medical Sciences, 1986, 292, 209-212.	0.4	36
90	Case Report: Cat Scratch Disease: An Infection Beyond the Lymph Node. American Journal of the Medical Sciences, 1986, 292, 389-390.	0.4	22

#	Article	IF	CITATIONS
91	VALIDITY OF FOOD CONSUMPTION HISTORIES IN A FOODBORNE OUTBREAK INVESTIGATION. American Journal of Epidemiology, 1986, 124, 859-863.	1.6	21
92	The Detection of Penicillin-Resistant Pneumococci: The Compliance of Hospital Laboratories with Recommended Methods. American Journal of Clinical Pathology, 1985, 84, 357-360.	0.4	13
93	ACUTE RESPIRATORY DISEASE HOSPITALIZATIONS AS A MEASURE OF IMPACT OF EPIDEMIC INFLUENZA. American Journal of Epidemiology, 1985, 122, 468-476.	1.6	145
94	The Incidence of Hepatitis B in Tennessee Prisoners. Journal of Infectious Diseases, 1985, 152, 214-217.	1.9	33
95	Seroepidemiology of Hepatitis B in Tennessee Prisoners. Journal of Infectious Diseases, 1984, 150, 450-459.	1.9	90
96	The Use and Efficacy of Child Restraint Devices. JAMA - Journal of the American Medical Association, 1984, 252, 2571.	3.8	61
97	Gonococcal perihepatitis in a female adolescent. Fitz-Hugh-Curtis syndrome. JAMA - Journal of the American Medical Association, 1978, 239, 339-340.	3.8	4
98	The breast cancer controversy. JAMA - Journal of the American Medical Association, 1977, 238, 2141-2142.	3.8	0